Thus, PD-L1 expression alone is insufficient to accurately predict HCC responsiveness to ICIs, and the relative expression levels of PD-L1 and CD80 may serve as better biomarkers for anti-CTLA-4 and anti-PD-1/PD-L1 therapies [108]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.